(NURE) Nuveen Short-Term REIT - Ratings and Ratios
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US67092P7069 • Real Estate
NURE: Real Estate, Investment Trusts, US Equities
The fund invests at least 80% of the sum of its net assets and the amount of any borrowings for investment purposes in REITs. The index is a subset of the Dow Jones U.S. Select REIT Index, which generally includes equity REITs traded on a national securities exchange in the U.S. that derive at least 75% of their total revenue from the ownership and operation of real estate assets and that have a minimum total market capitalization of $200 million at the time of their inclusion. It is non-diversified. ‣ Company URL: http://www.nuveen.com ‣ Domicile: United States
Additional Sources for NURE ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NURE ETF Overview
| Market Cap in USD | 50m |
| Category | Real Estate |
| TER | 0.35% |
| IPO / Inception | 2016-12-19 |
NURE ETF Ratings
| Growth 5y | 33.1% |
| Fundamental | - |
| Dividend | 61.6% |
| Rel. Strength Industry | -49.8 |
| Analysts | - |
| Fair Price Momentum | 27.70 USD |
| Fair Price DCF | - |
NURE Dividends
| Dividend Yield 12m | 3.61% |
| Yield on Cost 5y | 4.24% |
| Annual Growth 5y | 7.54% |
| Payout Consistency | 82.5% |
NURE Growth Ratios
| Growth Correlation 3m | -49.8% |
| Growth Correlation 12m | 82.7% |
| Growth Correlation 5y | 44.3% |
| CAGR 5y | 3.30% |
| CAGR/Mean DD 5y | 0.20 |
| Sharpe Ratio 12m | 0.18 |
| Alpha | -23.70 |
| Beta | 1.14 |
| Volatility | 19.61% |
| Current Volume | 4.9k |
| Average Volume 20d | 8.3k |
What is the price of NURE stocks?
As of January 23, 2025, the stock is trading at USD 30.93 with a total of 4,890 shares traded.
Over the past week, the price has changed by -0.19%, over one month by -2.64%, over three months by -5.19% and over the past year by +4.73%.
As of January 23, 2025, the stock is trading at USD 30.93 with a total of 4,890 shares traded.
Over the past week, the price has changed by -0.19%, over one month by -2.64%, over three months by -5.19% and over the past year by +4.73%.
Is Nuveen Short-Term REIT a good stock to buy?
Neither. Based on ValueRay Analyses, Nuveen Short-Term REIT is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 33.06 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NURE as of January 2025 is 27.70. This means that NURE is currently overvalued and has a potential downside of -10.44%.
Neither. Based on ValueRay Analyses, Nuveen Short-Term REIT is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 33.06 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NURE as of January 2025 is 27.70. This means that NURE is currently overvalued and has a potential downside of -10.44%.
Is NURE a buy, sell or hold?
Nuveen Short-Term REIT has no consensus analysts rating.
Nuveen Short-Term REIT has no consensus analysts rating.
What are the forecast for NURE stock price target?
According to ValueRays Forecast Model, NURE Nuveen Short-Term REIT will be worth about 30.9 in January 2026. The stock is currently trading at 30.93. This means that the stock has a potential upside of +0.03%.
According to ValueRays Forecast Model, NURE Nuveen Short-Term REIT will be worth about 30.9 in January 2026. The stock is currently trading at 30.93. This means that the stock has a potential upside of +0.03%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 30.9 | 0% |